Valentina Magri | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting	INTERNATIONAL JOURNAL OF CANCER	2019
Circulating tumor cells in right-and left-sided colorectal cancer	CANCERS	2019
Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients	CANCER MANAGEMENT AND RESEARCH	2019
Automated classification of focal breast lesions according to S-detect: validation and role as a clinical and teaching tool	JOURNAL OF ULTRASOUND	2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study	CANCER BIOLOGY & THERAPY	2018
EpCAM expressing circulating tumor cells in colorectal cancer	THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS	2017
Prolactin as a potential early predictive factor in metastatic non-small cell lung cancer patients treated with Nivolumab	ONCOLOGY	2017
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence	ANNALS OF ONCOLOGY	2017
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience	THE BREAST	2016
Eribulin in male patients with breast cancer: The first report of clinical outcomes	THE ONCOLOGIST	2016
Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)	ANNALS OF ONCOLOGY	2016
The promise of liquid biopsy in cancer: a clinical perspective	CHINESE JOURNAL OF CANCER RESEARCH	2015

Progetti di Ricerca

Value of PD-L1 positive CTCs as predictive marker of pCR during neoadjuvant chemotherapy in locally advanced breast cancer. Correlation with BRCA1/2 germline mutation.